default author photo

Tom Neff

FibroGen, Inc. - Department of Clinical Development

San Francisco, CA

United States

SCHOLARLY PAPERS

1

DOWNLOADS

190

TOTAL CITATIONS

9

Scholarly Papers (1)

1.

Gemcitabine/Nab-Paclitaxel and Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPC): A Phase 1/2 Trial

Number of pages: 91 Posted: 02 Mar 2019
Virginia Mason Medical Center, Virginia Mason Medical Center, Thomas Jefferson Medical Center, Georgetown Medical Center, Mayo Clinic - Florida, University of California, Los Angeles (UCLA) - Department of Medicine, Virginia Piper Cancer Institute, Ochsner Clinic Foundation, FibroGen, Inc. - Department of Clinical Development, FibroGen, Inc. - Department of Clinical Development, FibroGen, Inc. - Department of Clinical Development, FibroGen, Inc. - Department of Clinical Development, FibroGen, Inc. - Department of Clinical Development and FibroGen, Inc. - Department of Clinical Development
Downloads 190 (399,431)
Citation 9

Abstract:

Loading...

pamrevlumab, locally advanced pancreatic cancer, neoadjuvant chemotherapy